威海威高 www.weigaoholding.com  www.weigaogroup.com  www.wgbio.cn www.wegortho.com
山東威高集團(tuán)醫(yī)用高分子制品股份有限公司（「本公司」）及其附屬公司（「本集團(tuán)」）主要從事研發(fā)、生產(chǎn)及銷售醫(yī)用耗材、骨科材料、心臟支架等。本公司為國(guó)家高技術(shù)研究發(fā)展（863）計(jì)劃成果產(chǎn)業(yè)化基地、國(guó)家級(jí)高新技術(shù)企業(yè)。本集團(tuán)主要生產(chǎn)基地位于山東省威海市。

本集團(tuán)在中國(guó)注冊(cè)，擁有一個(gè)由18個(gè)銷售辦事處及21個(gè)客戶聯(lián)絡(luò)中心和107多家城市代表處組成的龐大銷售網(wǎng)絡(luò)，并已建立廣泛的客戶基礎(chǔ)，其產(chǎn)品銷售予5,400多家醫(yī)療單位和分銷商，其中包括醫(yī)院2800多家、血站400多家、其它醫(yī)療單位700多家和逾1,500家貿(mào)易公司。

本集團(tuán)生產(chǎn)的產(chǎn)品種類多達(dá)150余種，產(chǎn)品規(guī)格超過(guò)5000種，產(chǎn)品可分為六大系列，即1）一次性使用醫(yī)療耗材及原料，其中包括輸液（血）器、注射器、血袋與血液成份分離耗材、采血系列耗材、齒科耗材和麻醉系列耗材等，以及醫(yī)用PVC粒料和非PVC粒料等；2)骨科材料及工具，主要包括鋼板、螺釘?shù)葎?chuàng)傷治療耗材、脊柱系列耗材及正在發(fā)展的人工關(guān)節(jié)系列耗材；3)醫(yī)用針制品，主要包括靜脈針、注射針、留置針、采血針、異形針等系列制品；4)血液凈化系列耗材，主要包括穿刺針、血液回路管、透析器等腎科耗材，以及用于紅斑狼瘡、器官移植排異反應(yīng)、類風(fēng)濕關(guān)節(jié)炎等免疫系統(tǒng)疾病治療的免疫吸附柱，以及其它正在研發(fā)和注冊(cè)的LDL吸附柱、內(nèi)毒素吸附柱和乙肝病毒吸附柱等；5)心臟支架產(chǎn)品，主要包括藥物涂層心臟支架、球囊等；6)用于藥品包裝的預(yù)充式注射器。
“國(guó)家高技術(shù)研究發(fā)展（863）計(jì)劃成果產(chǎn)業(yè)化基地”、“國(guó)家級(jí)企業(yè)技術(shù)中心”，并建有企業(yè)博士后工作站。公司積極開(kāi)展產(chǎn)、學(xué)、研合作，與中科院長(zhǎng)春應(yīng)用化學(xué)研究所、中科院大連化學(xué)物理研究所、中科院沈陽(yáng)金屬研究所、第三軍醫(yī)大學(xué)、301醫(yī)院、哈工大（威海）等科研院所、院校緊密合作，并聘請(qǐng)了10位兩院院士做顧問(wèn)，依托其人才和科研力量，異地建立了九個(gè)威高集團(tuán)研發(fā)中心，立足行業(yè)制高點(diǎn)，消化吸收國(guó)際前沿技術(shù)，開(kāi)發(fā)具有自主知識(shí)產(chǎn)權(quán)的高科技產(chǎn)品。公司有60多個(gè)產(chǎn)品達(dá)到國(guó)內(nèi)外先進(jìn)水平，不少產(chǎn)品填補(bǔ)了國(guó)內(nèi)空白，20個(gè)產(chǎn)品入選國(guó)家863計(jì)劃、國(guó)家重點(diǎn)火炬計(jì)劃、國(guó)家高技術(shù)產(chǎn)業(yè)示范化工程、國(guó)家級(jí)重點(diǎn)新產(chǎn)品等國(guó)家各類項(xiàng)目，其中藥物涂層支架系統(tǒng)、預(yù)充式注射器、骨科植入材料等產(chǎn)品打破了國(guó)外公司對(duì)中國(guó)市場(chǎng)的壟斷。
集團(tuán)注重產(chǎn)品品牌的長(zhǎng)遠(yuǎn)發(fā)展，強(qiáng)調(diào)其產(chǎn)品質(zhì)量。自2001年11月以來(lái)，集團(tuán)的一次性使用無(wú)菌輸液器、一次性使用無(wú)菌輸血器及一次性使用無(wú)菌注射器的生產(chǎn)及服務(wù)的質(zhì)量體系獲中國(guó)醫(yī)療器械質(zhì)量認(rèn)證中心授予ISO9001：2000認(rèn)證、中國(guó)CMD認(rèn)證。從1999年12月，集團(tuán)的輸液器、輸血器、一次性使用注射器及塑料血袋等產(chǎn)品種類獲得由TÜV Product Service Gmbh頒發(fā)的CE認(rèn)證證書(shū)以來(lái)，本集團(tuán)已先后獲得一次性使用自動(dòng)取血器、一次性使用CT增強(qiáng)注射器造影劑針筒、一次性使用自毀式安全注射器、自動(dòng)縮回式安全注射器、骨科器械、金屬接骨板，脊柱內(nèi)固定系統(tǒng)，金屬接骨螺釘、帶鎖髓內(nèi)釘、一次性使用無(wú)菌注射針、一次性使用靜脈留置針、無(wú)針密閉輸液接頭等產(chǎn)品及體系的CE認(rèn)證。于2003年12月5日，集團(tuán)的產(chǎn)品質(zhì)量檢查中心獲中國(guó)實(shí)驗(yàn)室國(guó)家認(rèn)可委員會(huì)評(píng)為符合國(guó)家測(cè)試及定標(biāo)規(guī)定。于2005年6月23日，集團(tuán)擁有的 商標(biāo)被中國(guó)國(guó)家工商行政管理總局認(rèn)定為中國(guó)國(guó)內(nèi)醫(yī)療器械行業(yè)第一個(gè)中國(guó)馳名商標(biāo)。
目前，集團(tuán)的銷售主要在中國(guó)市場(chǎng)，本集團(tuán)正積極開(kāi)拓國(guó)際市場(chǎng)，產(chǎn)品已經(jīng)出口美國(guó)、德國(guó)、羅馬尼亞、澳大利亞和英國(guó)等30個(gè)國(guó)家和地區(qū)。
威海威高坐落在美麗的海濱城市威海。集團(tuán)下轄18個(gè)子公司，其中山東威高集團(tuán)醫(yī)用高分子制品股份有限公司為香港上市公司，已經(jīng)形成了醫(yī)療器械、藥品、航天電子、投資、房地產(chǎn)等五大業(yè)務(wù)領(lǐng)域齊頭并進(jìn)的發(fā)展格局。集團(tuán)現(xiàn)有總資產(chǎn)40多億元，員工9000多人，廠區(qū)占地面積125萬(wàn)平方米，擁有符合GMP要求的凈化車間20多萬(wàn)平方米，可生產(chǎn)300多個(gè)品種近30000種規(guī)格的醫(yī)療器械、藥品等產(chǎn)品。
20年來(lái)，威高堅(jiān)持“開(kāi)拓、創(chuàng)新、求實(shí)、鞏固”的建廠方針，以科技創(chuàng)新為動(dòng)力，以科學(xué)管理為后盾，促進(jìn)了企業(yè)的持續(xù)、快速、健康發(fā)展。公司較早在國(guó)內(nèi)開(kāi)發(fā)了一次性使用輸注耗材、手術(shù)縫合線、植入性醫(yī)用導(dǎo)管、心臟支架、留置針及各種異型針、血液凈化系列產(chǎn)品、骨科系列產(chǎn)品、機(jī)電一體化醫(yī)療器械、治療型注射液、生物診斷試劑、人造血漿等醫(yī)療器械產(chǎn)品和藥品，建立了極具規(guī)模的醫(yī)療用品工業(yè)園、骨科材料工業(yè)園、醫(yī)藥科技工業(yè)園、航天電子產(chǎn)品生產(chǎn)基地，現(xiàn)已成為中國(guó)最大的一次性使用醫(yī)療器械制造商。
威高集團(tuán)堅(jiān)持“以人為本、科技先行”的發(fā)展戰(zhàn)略，健全科學(xué)的管理模式，完善管理體系。公司在同行業(yè)中率先引進(jìn)和使用ERP、KPI等先進(jìn)管理軟件，產(chǎn)品通過(guò)了CE、ISO9001、ISO13485、3C等認(rèn)證，部分產(chǎn)品通過(guò)了美國(guó)FDA上市許可。公司的檢測(cè)中心通過(guò)了國(guó)家實(shí)驗(yàn)室認(rèn)可委員會(huì)的認(rèn)可。對(duì)科技的執(zhí)著追求，使威高集團(tuán)獲得了生存發(fā)展空間。公司被國(guó)家科技部等部委確定為“國(guó)家火炬計(jì)劃重點(diǎn)高新技術(shù)企業(yè)”、“國(guó)家高技術(shù)研究發(fā)展（863）計(jì)劃成果產(chǎn)業(yè)化基地”、“國(guó)家級(jí)企業(yè)技術(shù)中心”，并建有企業(yè)博士后工作站。公司積極開(kāi)展產(chǎn)、學(xué)、研合作，與中科院長(zhǎng)春應(yīng)用化學(xué)研究所、中科院大連化學(xué)物理研究所、中科院沈陽(yáng)金屬研究所、第三軍醫(yī)大學(xué)、301醫(yī)院、哈工大（威海）等科研院所、院校緊密合作，并聘請(qǐng)了10位兩院院士做顧問(wèn)，依托其人才和科研力量，異地建立了九個(gè)威高集團(tuán)研發(fā)中心，立足行業(yè)制高點(diǎn)，消化吸收國(guó)際前沿技術(shù)，開(kāi)發(fā)具有自主知識(shí)產(chǎn)權(quán)的高科技產(chǎn)品。公司有60多個(gè)產(chǎn)品達(dá)到國(guó)內(nèi)外先進(jìn)水平，不少產(chǎn)品填補(bǔ)了國(guó)內(nèi)空白，20個(gè)產(chǎn)品入選國(guó)家863計(jì)劃、國(guó)家重點(diǎn)火炬計(jì)劃、國(guó)家高技術(shù)產(chǎn)業(yè)示范化工程、國(guó)家級(jí)重點(diǎn)新產(chǎn)品等國(guó)家各類項(xiàng)目，其中藥物涂層支架系統(tǒng)、預(yù)充式注射器、骨科植入材料等產(chǎn)品打破了國(guó)外公司對(duì)中國(guó)市場(chǎng)的壟斷。
威高集團(tuán)堅(jiān)持不懈地實(shí)施名牌戰(zhàn)略，培育知名品牌。“潔瑞”商標(biāo)被認(rèn)定為“中國(guó)馳名商標(biāo)”，“潔瑞牌一次性使用無(wú)菌輸注醫(yī)療器械”被授予“中國(guó)名牌產(chǎn)品”稱號(hào)，“潔瑞”品牌被中國(guó)品牌研究院評(píng)定為中國(guó)醫(yī)療器械第一品牌。公司在全國(guó)30多個(gè)省、市、自治區(qū)建立了100多個(gè)銷售辦事機(jī)構(gòu)，同全國(guó)7000多家醫(yī)院、400多家血站、1800多家商業(yè)公司建立了長(zhǎng)期穩(wěn)定的關(guān)系。公司產(chǎn)品不僅暢銷到國(guó)內(nèi)30多個(gè)省、市、自治區(qū)，還直接出口到美國(guó)、歐盟、俄羅斯、南非、巴西等50多個(gè)國(guó)家和地區(qū)。
威高集團(tuán)將始終如一地堅(jiān)持科學(xué)發(fā)展觀，以“攜同白衣使者，開(kāi)創(chuàng)健康未來(lái)”為宗旨，以一次性醫(yī)療器械和藥品為主導(dǎo)，大力推進(jìn)產(chǎn)業(yè)結(jié)構(gòu)、產(chǎn)品結(jié)構(gòu)、體制結(jié)構(gòu)的調(diào)整，實(shí)現(xiàn)資本、技術(shù)和管理的國(guó)際化，矢志成為具世界競(jìng)爭(zhēng)力、亞洲領(lǐng)先、最受人尊敬的醫(yī)療器械和醫(yī)藥企業(yè)，為促進(jìn)我國(guó)醫(yī)療事業(yè)發(fā)展，提高人民健康水平做出新的貢獻(xiàn)。

威高集團(tuán)有限公司
地址： 山東省威海市世昌大道312號(hào) 
郵政編碼： 264209 
電話： 0631-5620486 
傳真： 0631-5620555 
Email： scb@weigaogroup.com 
網(wǎng)址： http://www.weigaoholding.com

Weigao Holding Company Limited. (“Weigao Holding”) and together with its subsidiaries (“Weigao”)is situated in Weihai City, a picturesque coastal city in China. Weigao Holding has 18 subsidiaries and has more than 9,000 employees and a total asset value of over RMB 4 billion (approximately US$0.59 billion). Shandong Weigao Group Medical Polymer Company Limited (“Weigao Group”), the major subsidiary of Weigao Holding, was listed on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited in 2004. Weigao covers a manufacturing area of 1,250,000 square meters including sterilized workshops with an area of 200,000 square meters that comply with GMP standards. It currently produces more than 250 types of medical products with more than 30,000 specifications.
In the past 20 years, Weigao rooted with the spirit of “development, innovation, pragmatism and consolidation”, and dedicated to attract talented people from the communities. Weigao focuses on technology driven innovative ideas and scientific management to transform the development mode and to advance the healthy and efficient growth of the business. In the domestic market, the company was the early mover to initiate the products of single use transfusion sets, medical suture, implantable medical catheters, coronary stents, intravenous catheters, irregular needles, blood purification, orthopaedic, electronic and mechanical medical products, medical injection fluid products, diagnostic reagents, artificial blood plasma and various medical products and medications. Weigao has established very large manufacturing bases in China for medical consumables, orthopaedic products, pharmaceuticals，and aerospace products. Today, Weigao is the leading single use medical consumable manufacturer in China.
Weigao established the mode of scientific management to achieve a smooth operation system. It is the first company in the industry to introduce and to successfully establish the management system of enterprise resource planning (ERP), key performance indicators (KPI) and other management system. Weigao Holding obtained the certifications of Conformité Européene (CE), ISO9000, ISO13485, China Compulsory Certification; and products registration of FDA 510K from Food and Drug Association (FDA). The award accredited to testing and inspection center of the company is also the only certification issued by China National Accreditation Board for Lab oratories in industry.
Weigao is devoted to innovation, technology and people and its commitment to technology is the value to its development. Weigao was accredited by the State Science and Technology Commission as the “Key High Technology & New Technological Enterprise under the State Torch Program”, the “Preferred Manufacturing Base for New Products Developed by the State High Technology Research Development (863) Program, and the technology center was also notarized by national governmental authorization as “State Enterprise Technology Center”. Weigao continues to develop into a conglomerate enterprise comprising of duties and responsibilities of manufacturing, education and research. The company established a post-doctoral research working center and collaborated with scientific research institutions and universities with strong scientific and research strength in setting up nine research and development centers. Ten academicians were appointed as consultants. There are more than 60 types of products which are further developed to enhance to an international level, and many of which filled the domestic blank. The company engaged in more than 20 national projects including Project 863, Project Torch, Model Project of National High Tech, The Key Technology Innovation Program of the State, and other projects. Currently, Weigao plays roles in the market of drug eluting stent (DES), pre-filled syringes and orthopedic material which were previously dominated by international players.
Weigao has been persistently sustain its brand value . The “Jierui” trademark is notarized by State Administration for Industry & Commerce as “China Famous Brand”; the “Jierui Single Use Sterile Infusion and Syringe Medical Device” was accredited by General Administration of Quality Supervision, Inspection and Quarantine of China as “the Most Famous Branded Product in China”; it is also notarized by China Brand Academy as “The No.1 Trademark” in the industry. Weigao has an extensive coverage of over 100 representative offices in 30 provinces, municipality and autonomous regions in China. Long term reliable relationship has also been well established with more than 7,000 hospitals, over 400 blood stations, and over 1800 other medical units. Today, Weigao’s products are not just the best-selling products in the domestic market; they are also exported to more than 50 countries and regions, including the United States, European countries, Russia, South Africa, and Brazil.
Weigao will continue to strive without reserve for the scientific development, and the mission is to “work with physicians to create healthy life for people in future”. Weigao will continue to improve and adjust the business structure, products mix and organizational structure. The goal of Weigao is to gradually transform from a domestic manufacturer to an internationally competitive, leading in Asia, and respectable conglomerate. Weigao, standing as a leading medical device company, continues to create and sustain a high level of performance in medical device products and pharmaceuticals. Weigao is well-positioned to continuing serving the medical community and improve people’s health for generations to come.